Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Growth in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 1,180.7% from the January 15th total of 211,600 shares. Approximately 25.5% of the company’s stock are sold short. Based on an average daily volume of 17,180,000 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Trading of Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new position in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 17.24% of the stock is owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Price Performance

NASDAQ:HEPA traded down $0.00 during midday trading on Wednesday, reaching $0.20. The stock had a trading volume of 19,712,740 shares, compared to its average volume of 40,912,324. Hepion Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $3.49. The firm’s fifty day simple moving average is $0.42 and its 200-day simple moving average is $0.59. The stock has a market capitalization of $1.38 million, a P/E ratio of -0.05 and a beta of 1.65.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.